Broad-spectrum drugs against viral agents

International Journal of Molecular Sciences

Volumn 9, Issue 9, 2008, Pages 1561-1594

  Christopher, Mary E ^a   Wong, Jonathan P ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

CpG; Cytokine; Influenza; Poly (ICLC); TLR

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; AMPHOTERICIN B; AMPLIGEN; ANTIVIRUS AGENT; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CASTANOSPERMINE; CHLOROQUINE; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED RNA; ENERGIX B; FOSCARNET; HEPATITIS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; OLIGONUCLEOTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT ALPHA INTERFERON A; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RETINOIC ACID; RIBAVIRIN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; VENEZUELAN EQUINE ENCEPHALITIS VIRUS VACCINE; VIRUS VACCINE; ZIDOVUDINE;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; BACTERIAL INFECTION; CLINICAL TRIAL; COCCIDIOSIS; DRUG SAFETY; ENCEPHALOMYELITIS; ENTEROBACTER INFECTION; ERYTHEMA; FLU LIKE SYNDROME; FRIEND LEUKEMIA; HEMORRHAGIC FEVER; HERPES SIMPLEX; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INJECTION SITE REACTION; INNATE IMMUNITY; LEISHMANIASIS; LISTERIOSIS; MYOCARDITIS; NONHUMAN; PAIN; REVIEW; SEMLIKI FOREST ALPHAVIRUS; VIREMIA; VIRUS INFECTION;

BACTERIA (MICROORGANISMS);

EID: 53549090456     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms9091561     Document Type: Review

References (217)

1. Wong, S.S.; Yuen, K.Y. Avian influenza virus infections in humans. Chest 2006, 129, 156-168.
2. Li, S.; Perdue, M.L.; Patzer, E. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic. Dev. Biol. (Basel) 2002, 110, 135-141.
3. Brooks, M.J.; Sasadeusz, J.J.; Tannock, G.A. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr. Opin. Pulm. Med. 2004, 10, 197-203.
4. Matrosovich, M.N.; Matrosovich, T.Y.; Gray, T.; Roberts, N.A.; Klenk, H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004, 78, 12665-12667.
5. WHO http://www.who.int/csr/disease/avian_influenza/en/, accessed 25 Feb 2008.
6. de Jong, M.D.; Tran, T.T.; Truong, H.K.; Vo, M.H.; Smith, G.J.; Nguyen, V.C.; Bach, V.C.; Phan, T.Q.; Do, Q.H.; Guan, Y.; et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353, 2667-2672.
7. Le, Q.M.; Kiso, M.; Someya, K.; Sakai, Y.T.; Nguyen, T.H.; Nguyen, K.H.; Pham, N.D.; Ngyen, H.H.; Yamada, S.; Muramoto, Y.; et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437, 1108.
8. Bright, R.A.; Medina, M.J.; Xu, X.; Perez-Oronoz, G.; Wallis, T.R.; Davis, X.M.; Povinelli, L.; Cox, N.J.; Klimov, A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366, 1175-1181.
9. Ashkar, A.A.; Bauer, S.; Mitchell, W.J.; Vieira, J.; Rosenthal, K.L., Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 2003, 77, 8948-8956.
10. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740-745.
11. McCluskie, M.J.; Weeratna, R.D. Novel adjuvant systems. Curr. Drug Targets Infect. Disord. 2001, 1, 263-271.
12. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20, 709-760.
13. Vollmer, J.; Weeratna, R.; Payette, P.; Jurk, M.; Schetter, C.; Laucht, M.; Wader, T.; Tluk, S.; Liu, M.; Davis, H.L.; et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34, 251-262.
14. Lund, J.M.; Alexopoulou, L.; Sato, A.; Karow, M.; Adams, N.C.; Gale, N.W.; Iwasaki, A.; Flavell, R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2004, 101, 5598-5603.
15. Kambayashi, T.; Assarsson, E.; Lukacher, A.E.; Ljunggren, H.G.; Jensen, P.E. Memory CD8+ T cells provide an early source of IFN-gamma. J. Immunol. 2003, 170, 2399-2408.
16. Weber, F.; Wagner, V.; Rasmussen, S.B.; Hartmann, R.; Paludan, S.R. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 2006, 80, 5059-5064.
17. Guillot, L.; Le Goffic, R.; Bloch, S.; Escriou, N.; Akira, S.; Chignard, M.; Si-Tahar, M., Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to doublestranded RNA and influenza A virus. J. Biol. Chem. 2005, 280, 5571-5580.
18. Chan, M.C.; Cheung, C.Y.; Chui, W.H.; Tsao, S.W.; Nicholls, J.M.; Chan, Y.O.; Chan, R.W.; Long, H.T.; Poon, L.L.; Guan, Y.; et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 2005, 6, 135-147.
19. Sivori, S.; Falco, M.; Delia Chiesa, M.; Carlomagno, S.; Vitale, M.; Moretta, L.; Moretta, A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA 2004, 101, 10116-10121.
20. Miller, J.L.; Anders, E.M. Virus-cell interactions in the induction of type 1 interferon by influenza virus in mouse spleen cells. J. Gen. Virol. 2003, 84(Pt 1), 193-202.
21. Kulka, M.; Alexopoulou, L.; Flavell, R.A.; Metcalfe, D.D. Activation of mast cells by doublestranded RNA: evidence for activation through Toll-like receptor 3. J. Allergy Clin. Immunol. 2004, 114, 174-182.
22. Fujita, H.; Asahina, A.; Mitsui, H.; Tamaki, K. Langerhans cells exhibit low responsiveness to double-stranded RNA. Biochem. Biophys. Res. Commun. 2004, 319, 832-839.
23. Coccia, E.M.; Severa, M.; Giacomini, E.; Monneron, D.; Remoli, M.E.; Julkunen, I.; Cella, M.; Lande, R.; Uze, G. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 2004, 34, 796-805.
24. Levy, H.B.; Baer, G.; Baron, S.; Buckler, C.E.; Gibbs, C.J.; Iadarola, M.J.; London, W.T.; Rice, J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132, 434-439.
25. Kende, M. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice. J. Biol. Response Mod. 1985, 4, 503-511.
26. Wang, J.; Matsukura, S.; Watanabe, S.; Adachi, M.; Suzaki, H. Involvement of Toll-like receptors in the immune response of nasal polyp epithelial cells. Clin. Immunol. 2007, 124, 345-352.
27. Ieki, K.; Matsukura, S.; Kokubu, F.; Kimura, T.; Kuga, H.; Kawaguchi, M.; Odaka, M.; Suzuki, S.; Watanabe, S.; Takeuchi, H.; et al. Double-stranded RNA activates RANTES gene transcription through co-operation of nuclear factor-kappaB and interferon regulatory factors in human airway epithelial cells. Clin. Exp. Allergy 2004, 34, 745-752.
28. Matsukura, S.; Kokubu, F.; Kurokawa, M.; Kawaguchi, M.; Ieki, K.; Kuga, H.; Odaka, M.; Suzuki, S.; Watanabe, S.; Takeuchi, H.; et al. Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. Clin. Exp. Allergy 2006, 36, 1049-1062.
29. Auch, C.J.; Saha, R.N.; Sheikh, F.G.; Liu, X.; Jacobs, B.L.; Pahan, K. Role of protein kinase R in double-stranded RNA-induced expression of nitric oxide synthase in human astroglia. FEBS Lett. 2004, 563, 223-228.
30. Chirigos, M.A.; Welker, R.; Schlick, E.; Saito, T.; Ruffmann, R. Vaccine adjuvant effects, and immune response, to synthetic polymers MVE and poly ICLC. Prog. Clin. Biol. Res. 1984, 161, 467-479.
31. Twilley, T.A.; Mason, L.; Talmadge, J.E.; Wiltrout, R.H. Increase in liver-associated natural killer activity by polyribonucleotides. Nat. Immun. Cell Growth Regul. 1987, 6, 279-290.
32. Wong, J.P.; Saravolac, E.G.; Sabuda, D.; Levy, H.B.; Kende, M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob. Agents Chemother. 1995, 39, 2574-2576.
33. Matsukura, S.; Kokubu, F.; Kurokawa, M.; Kawaguchi, M.; Ieki, K.; Kuga, H.; Odaka, M.; Suzuki, S.; Watanabe, S.; Homma, T.; et al. Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int. Arch. Allergy Immunol. 2007, 143(Suppl 1), 80-83.
34. Marshall-Clarke, S.; Downes, J.E.; Haga, I.R.; Bowie, A.G.; Borrow, P.; Pennock, J.L.; Grencis, R.K.; Rothwell, P. Polyinosinic acid is a ligand for toll-like receptor 3. J. Biol. Chem. 2007, 282, 24759-24766.
35. Sakurai, M; Iigo, M.; Sasaki, Y.; Nakagawa, K.; Fujiwara, Y.; Tamura, T.; Ohe, Y.; Bungo, M.; Saijo, N. Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect. Oncology 1990, 47, 251-256.
36. Bever, C.T., Jr.; McFarlin, D.E.; Levy, H.B. A comparison of interferon responses to poly ICLC in males and females. J. Interferon Res. 1985, 5, 423-428.
37. Bever, C.T., Jr.; McFarlin, D.E.; Levy, H.B. A comparison of interferon responses to poly ICLC in males and females. J. Interferon Res. 1992, Spec No, 85-90.
38. Sugiyama, T.; Hoshino, K.; Saito, M.; Yano, T.; Sasaki, I.; Yamazaki, C.; Akira, S.; Kaisho, T. Immunoadjuvant effects of polyadenylic: polyuridylic acids through TLR3 and TLR7. Int. Immunol. 2008, 20, 1-9.
39. Baer, G.M.; Shaddock, J.H.; Moore, S.A.; Yager, P.A.; Baron, S.S.; Levy, H.B. Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J. Infect. Dis. 1977, 136, 286-291.
40. Sidwell, R.W.; Huffman, J.H.; Barnard, D.L.; Smee, D.F.; Warren, R.P.; Chirigos, M.A.; Kende, M.; Huggins, J. Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Res. 1994, 25, 105-122.
41. Wong, J.P.; Nagata, L.P.; Christopher, M.E.; Salazar, A.M.; Dale, R.M. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 2005, 23, 2266-2268.
42. Robalino, J.; Browdy, C.L.; Prior, S.; Metz, A.; Parnell, P.; Gross, P.; Warr, G. Induction of antiviral immunity by double-stranded RNA in a marine invertebrate. J. Virol. 2004, 78, 10442-10448.
43. Stephen, E.L.; Sammons, M.L.; Pannier, W.L.; Baron, S.; Spertzel, R.O.; Levy, H.B. Effect of a nuclease-resistant derivative of polyriboinosinic- polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J. Infect. Dis. 1977, 136, 122-126.
44. Stephen, EX.; Hilmas, D.E.; Levy, H.B.; Spertzel, R.O. Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic- polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J. Infect. Dis. 1979, 139, 267-272.
45. Peres, A.; Seemayer, T.A.; Lapp, W.S. The effects of polyinosinic: polycytidylic acid (pI:C) on the GVH reaction: immunopathological observations. Clin. Immunol. Immunopathol. 1986, 39, 102-111.
46. Carter, W.A.; Strayer, D.U.S. Patent Application #20,050,137,154, 2004.
47. Wong, J.P.; Yang, H.; Nagata, L.; Kende, M.; Levy, H.; Schnell, G.; Blasetti, K. Liposomemediated immunotherapy against respiratory influenza virus infection using double-stranded RNApoly ICLC. Vaccine 1999, 17, 1788-1795.
48. Kende, M. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice. J. Biol. Response Mod. 1985, 4, 503-511.
49. Kende, M.; Lupton, H.W.; Rill, W.L.; Gibbs, P.; Levy, H.B.; Canonico, P.G. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death. Antimicrob. Agents Chemother. 1987, 31, 1194-1198.
50. Olsen, A.L.; Morrey, J.D.; Smee, D.F.; Sidwell, R.W. Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res. 2007, 75, 104-112.
51. Barnard, D.L.; Day, C.W.; Bailey, K.; Heiner, M.; Montgomery, R.; Lauridsen, L.; Chan, P.K.; Sidwell, R.W. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 2006, 17, 275-284.
52. Morrey, J.D.; Day, C.W.; Julander, J.G.; Blatt, L.M.; Smee, D.F.; Sidwell, R.W. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir. Chem. Chemother. 2004, 15, 101-109.
53. Kende, M.; Lupton, H.W.; Rill, W.L.; Levy, H.B.; Canonico, P.G. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.. Antimicrob. Agents Chemother. 1987, 31, 986-990.
54. Rettenmaier, M.A.; Berman, M.L.; DiSaia, P.J. Treatment of advanced ovarian cancer with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC]. Gynecol. Oncol. 1986, 24, 359-361.
55. Ichinohe, T.; Watanabe, I.; Ito, S.; Fujii, H.; Moriyama, M.; Tamura, S.; Takahashi, H.; Sawa, H.; Chiba, J.; Kurata, T.; et al. Synthetic double-stranded RNA poly(LC) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 2005, 79, 2910-2919.
56. Ichinohe, T.; Tamura, S.; Kawaguchi, A.; Ninomiya, A.; Imai, M.; Itamura, S.; Odagiri, T.; Tashiro, M.; Takahashi, H.; Sawa, H.; et al. Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine. J. Infect. Dis. 2007, 196, 1313-1320.
57. Ichinohe, T.; Kawaguchi, A.; Tamura, S.; Takahashi, H.; Sawa, H.; Ninomiya, A.; Imai, M.; Itamura, S.; Odagiri, T.; Tashiro, M.; et al. Intranasal immunization with H5N1 vaccine plus Poly LPoly C(12)U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect. 2007, 9, 1333-1340.
58. DeCicco, K.L.; Youngdahl, J.D.; Ross, A.C. All-trans-retinoic acid and polyriboinosinic: Polyribocytidylic acid in combination potentiate specific antibody production and cell-mediated immunity. Immunology 2001, 104, 341-348.
59. Harrington, D.G.; Crabbs, C.L.; Hilmas, D.E.; Brown, J.R.; Higbee, G.A.; Cole, F.E.J.; Levy, H.B. Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid. polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine.. Infect. Immun. 1979, 24, 160-166.
60. Houston, W.E.; Crabbs, C.L.; Stephen, EX.; Levy, H.B. Modified polyriboinosinicpolyribocytidylic acid, an irnmunological adjuvant. Infect. Immun. 1976, 14, 318-319.
61. Siddiqi, N.J.; Puri, S.K.; Dutta, G.P.; Maheshwari, R.K.; Pandey, V.C. Studies on hepatic oxidative stress and antioxidant defence system during chloroquine/poly ICLC treatment of Plasmodium yoelii nigeriensis infected mice. Mol. Cell. Biochem. 1999, 194, 179-183.
62. Montefiori, D.C.; Robinson, W.E.J.; Mitchell, W.M. In vitro evaluation of mismatched doublestranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. AIDS Res. Hum. Retroviruses 1989, 5, 193-203.
63. Pantelic, L.; Sivakumaran, H.; Urosevic, N. Differential induction of antiviral effects against West Nile virus in primary mouse macrophages derived from flavivirus-susceptible and congenic resistant mice by alpha/beta interferon and poly(I-C). J. Virol. 2005, 79, 1753-1764.
64. Coppenhaver, D.H.; Singh, I.P.; Sarzotti, M.; Levy, H.B.; Baron, S. Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. Am. J. Trop. Med. Hyg. 1995, 52, 34-40.
65. Ewel, C.H.; Urba, W.J.; Kopp, W.C.; Smith, J.W., 2nd; Steis, R.G.; Rossio, J.L.; Longo, D.L.; Jones, M.J.; Alvord, W.G.; Pinsky, CM.; et al. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res. 1992, 52, 3005-3010.
66. Gatmaitan, B.G.; Legaspi, R.C.; Levy, H.B.; Lerner, A.M. Modified polyriboinosinicpolyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits. Antimicrob. Agents Chemother. 1980, 17, 49-54.
67. Traynor, T.R.; Majde, J.A.; Bohnet, S.G.; Krueger, J.M. Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections. Life Sci. 2004, 74, 2563-2576.
68. Robinson, R.A.; DeVita, V.T.; Levy, H.B.; Baron, S.; Hubbard, S.P.; Levine, A.S. A phase I-II trial of multiple-dose polyriboinosic- polyribocytidylic acid in patieonts with leukemia or solid tumors. J. Natl. Cancer Inst. 1976, 57, 599-602.
69. Krown, S.E.; Kerr, D.; Stewart, W.E., 2nd; Field, A.K.; Oettgen, H.F. Phase I trials of poly(LC) complexes in advanced cancer. J. Biol. Response Mod. 1985, 4, 640-649.
70. Lampkin, B.C.; Levine, A.S.; Levy, H.; Krivit, W.; Hammond, D. Phase II trial of poly(I,C)-LC, an interferon inducer, in the treatment of children with acute leukemia and neuroblastoma: A report from the Children's Cancer Study Group. J. Biol. Response Mod. 1985, 4, 531-537.
71. Lampkin, B.C.; Levine, A.S.; Levy, H.; Krivit, W.; Hammond, D. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group. Cancer Res. 1985, 45(11 Pt2), 5904-5909.
72. Durie, B.G.; Levy, H.B.; Voakes, J.; Jett, J.R.; Levine, A.S. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. J. Biol. Response Mod. 1985, 4, 518-524.
73. McFarlin, D.E.; Bever, C.T.; Salazar, A.M.; Levy, H.B. A preliminary trial of poly(I,C)-LC in multiple sclerosis. J. Biol. Response Mod. 1985, 4, 544-548.
74. Stevenson, H.C.; Abrams, P.G.; Schoenberger, C.S.; Smalley, R.B.; Herberman, R.B.; Foon, K.A. A phase I evaluation of poly(I,C)-LC in cancer patients. J. Biol. Response Mod. 1985, 4, 650-655.
75. Hawkins, M.J.; Levin, M.; Borden, E.C. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J. Biol. Response Mod. 1985, 4, 664-668.
76. Bever, C.T., Jr.; McFarland, H.F.; Levy, H.B.; McFarlin, D.E. Cortisol induction by poly ICLC: implications for clinical trials of interferon. Ann. Neurol. 1988, 23, 196-199.
77. Giantonio, B.J.; Hochster, H.; Blum, R.; Wiernik, P.H.; Hudes, G.R.; Kirkwood, J.; Trump, D.; Oken, M.M. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest. New Drugs 2001, 19, 89-92.
78. Zare, F.; Bokarewa, M.; Nenonen, N.; Bergstrom, T.; Alexopoulou, L.; Flavell, R.A.; Tarkowski, A. Arthritogenic properties of double-stranded (viral) RNA. J. Immunol. 2004, 172, 5656-5663.
79. Levy, H.B.; Riley, F.L. A comparison of immune modulating effects of interferon and interferon inducers. In Lymphokines, Openheim, J., Pick, A., Eds.; Academic Press: New York, 1983; Vol. 8, pp 303-322.
80. Fortier, M.E.; Kent, S.; Ashdown, H.; Poole, S.; Boksa, P.; Luheshi, G.N. The viral mimic, polyinosinic: polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287, R759-766.
81. Chadha, K.C.; Dembinski, W.E.; Dunn, C.B.; Aradi, J.; Bardos, T.J.; Dunn, J.A.; Ambrus, J.L., Sr. Effect of increasing thiolation of the polycytidylic acid strand of poly Lpoly C on the alpha, beta and gamma interferon-inducing properties, antiviral and antiproliferative activities. Antiviral Res. 2004, 64, 171-177.
82. Marshall, J.D.; Hessel, E.M.; Gregorio, J.; Abbate, C.; Yee, P.; Chu, M.; Van Nest, G.; Coffman, R.L.; Fearon, K.L. Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Nucleic Acids Res. 2003, 31, 5122-5133.
83. Rankin, R.; Pontarollo, R.; Ioannou, X.; Krieg, A.M.; Hecker, R.; Babiuk, L.A.; van Drunen Littel-van den Hurk, S. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001, 11, 333-340.
84. Kurata, K.; Iwata, A.; Masuda, K.; Sakaguchi, M.; Ohno, K.; Tsujimoto, H. Identification of CpG oligodeoxynucleotide sequences that induce IFN-gamma production in canine peripheral blood mononuclear cells. Vet. Immunol. Immunopathol. 2004, 102, 441-450.
85. Hartmann, G.; Weeratna, R.D.; Ballas, Z.K.; Payette, P.; Blackwell, S.; Suparto, I.; Rasmussen, W.L.; Waldschmidt, M.; Sajuthi, D.; Purcell, R.H.; et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 2000, 164, 1617-1624.
86. Fearon, K.; Marshall, J.D.; Abbate, C.; Subramanian, S.; Yee, P.; Gregorio, J.; Teshima, G.; Ott, G.; Tuck, S.; Van Nest, G.; et al. A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur. J. Immunol. 2003, 33, 2114-2122.
87. Cornelie, S.; Hoebeke, J.; Schacht, A.M.; Bertin, B.; Vicogne, J.; Capron, M.; Riveau, G. Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosinephosphate-guanine motif recognition. J. Biol. Chem. 2004, 279, 15124-15129.
88. Klinman, D.M.; Currie, D.; Gursel, I.; Verthelyi, D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 2004, 199, 201-216.
89. Ishii, K.J.; Gursel, I.; Gursel, M.; Klinman, D.M. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr. Opin. Mol. Ther. 2004, 6, 166-174.
90. Yi, A.K.; Peckham, D.W.; Ashman, R.F.; Krieg, A.M. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int. Immunol. 1999, 11, 2015-2024.
91. Hartmann, G.; Weiner, G.J.; Krieg, A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 1999, 96, 9305-9310.
92. Bernasconi, N.L.; Onai, N.; Lanzavecchia, A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101, 4500-4504.
93. Kerkmann, M.; Rothenfusser, S.; Hornung, V.; Towarowski, A.; Wagner, M.; Sarris, A.; Giese, T.; Endres, S.; Hartmann, G. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 2003, 170, 4465-4474.
94. Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; Jahrsdorfer, B.; Giese, T.; Endres, S.; Hartmann, G., Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168, 4531-4537.
95. Amcheslavsky, A.; Zou, W.; Bar-Shavit, Z. Toll-like receptor 9 regulates tumor necrosis factoralpha expression by different mechanisms. Implications for osteoclastogenesis. J. Biol. Chem. 2004, 279, 54039-54045.
96. Zhao, Q.; Matson, S.; Herrera, C.J.; Fisher, E.; Yu, H.; Krieg, A.M., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 1993, 3, 53-66.
97. Agrawal, S.; Temsamani, J.; Galbraith, W.; Tang, J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 1995, 28, 7-16.
98. Iversen, P.L.; Zhu, S.; Meyer, A.; Zon, G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. 1992, 2, 211-222.
99. Klinman, D.M.; Currie, D. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides. Clin. Exp. Immunol. 2003, 133, 227-232.
100. Verthelyi, D.; Gursel, M.; Kenney, R.T.; Lifson, J.D.; Liu, S.; Mican, J.; Klinman, D.M. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 2003, 170, 4717-4723.
101. Krieg, A.M.; Love-Homan, L.; Yi, A.K.; Harty, J.T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 1998, 161, 2428-2434.
102. Krieg, A.M.; Efler, S.M.; Wittpoth, M.; Al Adhami, M.J.; Davis, H.L. Induction of systemic THl-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 2004, 27, 460-471.
103. Christopher, M.E.; Wong, J.P. Broad-spectrum antiviral defence against influenza viruses using nucleic acid-based immunomodulators. In Recent Developments on the Avian Influenza (H5N1) Crisis, Wong, J. P., Ed.; Transworld Research Network: Trivandrum, 2006; pp 85-118.
104. Dong, L.; Mori, I.; Hossain, M.J.; Liu, B.; Kimura, Y. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J. Gen. Virol. 2003, 84(Pt6), 1623-1628.
105. Jahrsdorfer, B.; Muhlenhoff, L.; Blackwell, S.E.; Wagner, M.; Poeck, H.; Hartmann, E.; Jox, R.; Giese, T.; Emmerich, B.; Endres, S.; et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin. Cancer Res. 2005, 11, 1490-1499.
106. Gursel, I.; Gursel, M.; Ishii, K.J.; Klinman, D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 2001, 167, 3324-3328.
107. Elkins, K.L.; Rhinehart-Jones, T.R.; Stibitz, S.; Conover, J.S.; Klinman, D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 1999, 162, 2291-2298.
108. Klinman, D.M. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998, 8, 181-184.
109. Klinman, D.M.; Conover, J.; Coban, C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 1999, 67, 5658-5663.
110. Gomis, S.; Babiuk, L.; Godson, D.L.; Allan, B.; Thrush, T.; Townsend, H.; Willson, P.; Waters, E.; Hecker, R.; Potter, A. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect. Immun. 2003, 71, 857-863.
111. Verthelyi, D.; Ishii, K.J.; Gursel, M.; Takeshita, F.; Klinman, D.M. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 2001, 166, 2372-2377.
112. Zimmermann, S.; Egeter, O.; Hausmann, S.; Lipford, G.B.; Rocken, M.; Wagner, H.; Heeg, K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 1998, 160, 3627-3630.
113. Juffermans, N.P.; Leemans, J.C.; Florquin, S.; Verbon, A.; Kolk, A.H.; Speelman, P.; van Deventer, S.J.; van der Poll, T. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect. Immun. 2002, 70, 147-152.
114. Klinman, D.M.; Verthelyi, D.; Takeshita, F.; Ishii, K.J. Immune recognition of foreign DNA: A cure for bioterrorism? Immunity 1999, 11, 123-129.
115. Gramzinski, R.A.; Doolan, D.L.; Sedegah, M.; Davis, H.L.; Krieg, A.M.; Hoffman, S.L. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. 2001, 69, 1643-1649.
116. Olbrich, A.R.; Schimmer, S.; Heeg, K.; Schepers, K.; Schumacher, T.N.; Dittmer, U. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J. Virol. 2002, 76, 11397-11404.
117. Pyles, R.B.; Higgins, D.; Chalk, C; Zalar, A.; Eiden, J.; Brown, C; Van Nest, G.; Stanberry, L.R. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 2002, 76, 11387-11396.
118. Sethi, S.; Lipford, G.; Wagner, H.; Kretzschmar, H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 2002, 360, 229-230.
119. Dalloul, R.A.; Lillehoj, H.S.; Okamura, M.; Xie, H.; Min, W.; Ding, X.; Heckert, R.A. In vivo effects of CpG oligodeoxynucleotide on Eimeria infection in chickens. Avian Dis. 2004, 48, 783-790.
120. Moldoveanu, Z.; Love-Homan, L.; Huang, W.Q.; Krieg, A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998, 16, 1216-1224.
121. McCluskie, M.J.; Davis, H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 2000, 19, 413-422.
122. Hayashi, M.; Satou, E.; Ueki, R.; Yano, M.; Miyano-Kurosaki, N.; Fujii, M.; Takaku, H. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator. Biochem. Biophys. Res. Commun. 2005, 329, 230-236.
123. Joseph, A.; Louria-Hayon, I.; Plis-Finarov, A.; Zeira, E.; Zakay-Rones, Z.; Raz, E.; Hayashi, T.; Takabayashi, K.; Barenholz, Y.; Kedar, E. Liposomal immunostimulatory DNA sequence (ISSODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20, 3342-3354.
124. Klinman, D.M.; Ishii, K.J.; Gursel, M.; Gursel, I.; Takeshita, S.; Takeshita, F. Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000, 13, 289-296.
125. Cooper, C.L.; Davis, H.L.; Morris, M.L.; Efler, S.M.; Krieg, A.M.; Li, Y.; Laframboise, C; Al Adhami, M.J.; Khaliq, Y.; Seguin, I.; et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22, 3136-3143.
126. Halperin, S.A.; Van Nest, G.; Smith, B.; Abtahi, S.; Whiley, H.; Eiden, J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21, 2461-2467.
127. Friedberg, J.W.; Kim, H.; McCauley, M.; Hessel, E.M.; Sims, P.; Fisher, D.C.; Nadler, L.M.; Coffman, R.L.; Freedman, A.S. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/betainducible gene expression, without significant toxicity. Blood 2005, 105, 489-495.
128. Siegrist, C.A.; Pihlgren, M.; Tougne, C; Efler, S.M.; Morris, M.L.; AlAdhami, M.J.; Cameron, D.W.; Cooper, C.L.; Heathcote, J.; Davis, H.L.; et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23, 615-622.
129. Speiser, D.E.; Lienard, D.; Rufer, N.; Rubio-Godoy, V.; Rimoldi, D.; Lejeune, F.; Krieg, A.M.; Cerottini, J.C.; Romero, P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IF A, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115, 739-746.
130. Paul, S. Technology evaluation: CpG-7909, Coley. Curr. Opin. Mol. Ther. 2003, 5, 553-559.
131. Cooper, C.L.; Davis, H.L.; Morris, M.L.; Efler, S.M.; Adhami, M.A.; Krieg, A.M.; Cameron, D.W.; Heathcote, J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 2004, 24, 693-701.
132. Babiuk, S.; Baca-Estrada, M.E.; Middleton, D.M.; Hecker, R.; Babiuk, L.A.; Foldvari, M. Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr. Drug. Deliv. 2004, 1, 9-15.
133. Zakhartchouk, A.N.; Sharon, C; Satkunarajah, M.; Auperin, T.; Viswanathan, S.; Mutwiri, G.; Petric, M.; See, R.H.; Brunham, R.C.; Finlay, B.B.; et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 2007, 25, 136-143.
134. Bao, M.; Zhang, Y.; Wan, M.; Dai, L.; Hu, X.; Wu, X.; Wang, L.; Deng, P.; Wang, J.; Chen, J.; et al. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin. Immunol. 2006, 118, 180-187.
135. Rankin, R.; Pontarollo, R.; Gomis, S.; Karvonen, B.; Willson, P.; Loehr, B.I.; Godson, D.L.; Babiuk, L.A.; Hecker, R.; van Drunen Littel-van den Hurk, S. CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 2002, 20, 3014-3022.
136. Kwissa, M.; Amara, R.R.; Robinson, H.L.; Moss, B.; Alkan, S.; Jabbar, A.; Villinger, F.; Pulendran, B. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J. Exp. Med. 2007, 204, 2733-2746.
137. Kumar, S.; Jones, T.R.; Oakley, M.S.; Zheng, H.; Kuppusamy, S.P.; Taye, A.; Krieg, A.M.; Stowers, A.W.; Kaslow, D.C.; Hoffman, S.L. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun. 2004, 72, 949-957.
138. Wooldridge, J.E.; Ballas, Z.; Krieg, A.M.; Weiner, G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997, 89, 2994-2998.
139. Klinman, D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2003, 2, 305-315.
140. Katsumi, A.; Emi, N.; Abe, A.; Hasegawa, Y.; Ito, M.; Saito, H. Humoral and cellular immunity to an encoded protein induced by direct DNA injection. Hum. Gene Ther. 1994, 5, 1335-1339.
141. Mor, G.; Singla, M.; Steinberg, A.D.; Hoffman, S.L.; Okuda, K.; Klinman, D.M. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 1997, 8, 293-300.
142. Gilkeson, G.S.; Conover, J.; Halpern, M.; Pisetsky, D.S.; Feagin, A.; Klinman, D.M. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J. Immunol. 1998, 161, 3890-3895.
143. Segal, B.M.; Klinman, D.M.; Shevach, E.M. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 1997, 158, 5087-5090.
144. Segal, B.M.; Chang, J.T.; Shevach, E.M. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 2000, 164, 5683-5688.
145. Bachmaier, K.; Neu, N.; de la Maza, L.M.; Pal, S.; Hessel, A.; Penninger, J.M. Chlamydia infections and heart disease linked through antigenic mimicry. Science 1999, 283, 1335-1339.
146. Zeuner, R.A.; Verthelyi, D.; Gursel, M.; Ishii, K.J.; Klinman, D.M. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 2003, 48, 1701-1707.
147. Cowdery, J.S.; Chace, J.H.; Yi, A.K.; Krieg, A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 1996, 156, 4570-4575.
148. Hartmann, G.; Krug, A.; Waller-Fontaine, K.; Endres, S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 1996, 2, 429-438.
149. Sparwasser, T.; Miethke, T.; Lipford, G.; Borschert, K.; Hacker, H.; Heeg, K.; Wagner, H. Bacterial DNA causes septic shock. Nature 1997, 386, 336-337.
150. Heikenwalder, M.; Polymenidou, M.; Junt, T.; Sigurdson, C; Wagner, H.; Akira, S.; Zinkernagel, R.; Aguzzi, A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 2004, 10, 187-192.
151. Jiao, X.; Wang, R.Y.; Qiu, Q.; Alter, H.J.; Shih, J.W. Enhanced hepatitis C virus NS3 specific Thl immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J. Gen. Virol. 2004, 85(Pt6), 1545-1553.
152. Mui, B.; Raney, S.G.; Semple, S.C.; Hope, M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 2001, 298, 1185-1192.
153. Benimetskaya, L.; Wittenberger, T.; Stein, C.A.; Hofmann, H.P.; Weller, C; Lai, J.C.; Miller, P.; Gekeler, V. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Clin. Cancer Res. 2004, 10, 3678-3688.
154. Diwan, M.; Tafaghodi, M.; Samuel, J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 2002, 85, 247-262.
155. Hayashi, M.; Kuwahara, M.; Ogata, M.; Miyao-Kurosaki, N.; Abel, T.; Ueki, R.; Yano, M.; Fujii, M.; Hartmann, G.; Takaku, H. Evaluating the immune responses stimulated by CpG oligodeoxynucleotides. Nucleic Acids Res. Suppl. 2003, 323-324.
156. Kandimalla, E.R.; Bhagat, L.; Yu, D.; Cong, Y.; Tang, J.; Agrawal, S. Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug. Chem. 2002, 13, 966-974.
157. Kandimalla, E.R.; Bhagat, L.; Zhu, F.G.; Yu, D.; Cong, Y.P.; Wang, D.; Tang, J.X.; Tang, J.Y.; Knetter, C.F.; Lien, E.; et al. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc. Natl. Acad. Sci. USA 2003, 100, 14303-14308.
158. Diebold, S.S.; Massacrier, C; Akira, S.; Paturel, C; Morel, Y.; Reis e Sousa, C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 2006, 36, 3256-3267.
159. Wang, J.P.; Liu, P.; Latz, E.; Golenbock, D.T.; Finberg, R.W.; Libraty, D.H. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J. Immunol. 2006, 177, 7114-7121.
160. Hornung, V.; Barchet, W.; Schlee, M.; Hartmann, G. RNA recognition via TLR7 and TLR8. Handb. Exp. Pharmacol. 2008, 183, 71-86.
161. Novak, N.Y.; Yu, C.F.; Bieber, T.; Allam, J.P. Toll-like receptor 7 agonists and skin. Drug News Perspect. 2008, 21, (3), 158-165.
162. Hanten, J.A.; Vasilakos, J.P.; Riter, C.L.; Neys, L.; Lipson, K.E.; Alkan, S.S.; Birmachu, W. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008, 9, 39.
163. Butchi, N.B.; Pourciau, S.; Du, M.; Morgan, T.W.; Peterson, K.E. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists. J. Immunol. 2008, 180, 7604-7612.
164. Birmachu, W.; Gleason, R.M.; Bulbulian, B.J.; Riter, C.L.; Vasilakos, J.P.; Lipson, K.E.; Nikolsky, Y. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunol. 2007, 8, 26.
165. Gantier, M.P.; Tong, S.; Behlke, M.A.; Xu, D.; Phipps, S.; Foster, P.S.; Williams, B.R. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J. Immunol. 2008, 180, 2117-2124.
166. Delgado, M.A.; Elmaoued, R.A.; Davis, A.S.; Kyei, G.; Deretic, V. Toll-like receptors control autophagy. E.M.B.O. J. 2008, 27, 1110-1121.
167. Wang, J.P.; Bowen, G.N.; Padden, C; Cerny, A.; Finberg, R.W.; Newburger, P.E.; Kurt-Jones, E.A. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 2008, 112, 2028-2034.
168. Wu, C.C.; Hayashi, T.; Takabayashi, K.; Sabet, M.; Smee, D.F.; Guiney, D.D.; Cottam, H.B.; Carson, D.A. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl. Acad. Sci. USA 2007, 104, 3990-3995.
169. Hammerbeck, D.M.; Burleson, G.R.; Schuller, C.J.; Vasilakos, J.P.; Tomai, M.; Egging, E.; Cochran, F.R.; Woulfe, S.; Miller, R.L. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 2007, 73, 1-11.
170. Krug, A. Nucleic acid recognition receptors in autoimmunity. Handb. Exp. Pharmacol. 2008, 183, 129-151.
171. Deane, J.A.; Pisitkun, P.; Barrett, R.S.; Feigenbaum, L.; Town, T.; Ward, J.M.; Flavell, R.A.; Bolland, S. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007, 27, 801-810.
172. Barrat, F.J.; Meeker, T.; Chan, J.H.; Guiducci, C; Coffman, R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37, 3582-3586.
173. Berghöfer, B.; Frommer, T.; Haley, G.; Fink, L.; Bein, G.; Hackstein, H. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 2006, 177, 2088-2096.
174. Matrosovich, M.N.; Matrosovich, T.Y.; Gray, T.; Roberts, N.A.; Klenk, H.D. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. USA 2004, 101, 4620-4624.
175. Olofsson, S.; Kumlin, U.; Dimock, K.; Arnberg, N. Avian influenza and sialic acid receptors: more than meets the eye? Lancet Infect. Dis. 2005, 5, 184-188.
176. Sidwell, R.W.; Huffman, J.H.; Bailey, K.W.; Wong, M.H.; Nimrod, A.; Panet, A. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice. Antimicrob. Agents Chemother. 1996, 40, 2626-2631.
177. Oda, T.; Akaike, T.; Hamamoto, T.; Suzuki, F.; Hirano, T.; Maeda, H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989, 244, 974-976.
178. Kawaguchi, M.; Kokubu, F.; Kuga, H.; Tomita, T.; Matsukura, S.; Suzaki, H.; Huang, S.K.; Adachi, M. Influenza virus A stimulates expression of eotaxin by nasal epithelial cells. Clin. Exp. Allergy 2001, 31, 873-880.
179. Matsukura, S.; Kokubu, F.; Kubo, H.; Tomita, T.; Tokunaga, H.; Kadokura, M.; Yamamoto, T.; Kuroiwa, Y.; Ohno, T.; Suzaki, H.; et al. Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am. J. Respir. Cell. Mol. Biol. 1998, 18, 255-264.
180. Schultz-Cherry, S.; Hinshaw, V.S. Influenza virus neuraminidase activates latent transforming growth factor beta. J. Virol. 1996, 70, 8624-8629.
181. Ohyama, K.; Sano, T.; Toyoda, H. Predominant contribution of IFN-beta expression to apoptosis induction in human uterine cervical fibroblast cells by influenza-virus infection. Biol. Pharm. Bull. 2004, 27, 1750-1757.
182. Liu, B.; Mori, I.; Hossain, M.J.; Dong, L.; Chen, Z.; Kimura, Y. Local immune responses to influenza virus infection in mice with a targeted disruption of perforin gene. Microb. Pathog. 2003, 34, 161-167.
183. He, X.S.; Draghi, M.; Mahmood, K.; Holmes, T.H.; Kemble, G.W.; Dekker, C.L.; Arvin, A.M.; Parham, P.; Greenberg, H.B. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J. Clin. Invest. 2004, 114, 1812-1819.
184. Seo, S.H.; Peiris, M.; Webster, R.G. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J. Virol. 2002, 76, 4886-4890.
185. Cheung, C.Y.; Poon, L.L.; Lau, A.S.; Luk, W.; Lau, Y.L.; Shortridge, K.F.; Gordon, S.; Guan, Y.; Peiris, J.S. Induction of pro inflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002, 360, 1831-1837.
186. Dybing, J.K.; Schultz-Cherry, S.; Swayne, D.E.; Suarez, D.L.; Perdue, M.L. Distinct pathogenesis of Hong Kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. J. Virol. 2000, 74, 1443-1450.
187. Klenk, H.D. Infection of the endothelium by influenza viruses. Thromb. Haemost. 2005, 94, 262-265.
188. Rimmelzwaan, G.F.; Kuiken, T.; van Amerongen, G.; Bestebroer, T.M.; Fouchier, R.A.; Osterhaus, A.D. A primate model to study the pathogenesis of influenza A (H5N1) virus infection. Avian Dis. 2003, 47 (3 Suppl), 931-933.
189. Uiprasertkul, M.; Puthavathana, P.; Sangsiriwut, K.; Pooruk, P.; Srisook, K.; Peiris, M.; Nicholls, J.M.; Chokephaibulkit, K.; Vanprapar, N.; Auewarakul, P. Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis. 2005, 11, 1036-1041.
190. Koyama, S.; Sato, E.; Tsukadaira, A.; Haniuda, M.; Numanami, H.; Kurai, M.; Nagai, S.; Izumi, T. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur. Respir. J. 2002, 20, 1449-1456.
191. Iwasaki, T.; Itamura, S.; Nishimura, H.; Sato, Y.; Tashiro, M.; Hashikawa, T.; Kurata, T. Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation. Acta. Neuropathol. 2004, 108, 485-492.
192. Lipatov, A.S.; Andreansky, S.; Webby, R.J.; Hulse, D.J.; Rehg, J.E.; Krauss, S.; Perez, D.R.; Doherty, P.C.; Webster, R.G.; Sangster, M.Y. Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: the role of cytokines and B- and T-cell responses. J. Gen. Virol. 2005, 86(Pt 4), 1121-1130.
193. Seo, S.H.; Hoffmann, E.; Webster, R.G. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res. 2004, 103, 107-113.
194. Tumpey, T.M.; Lu, X.; Morken, T.; Zaki, S.R.; Katz, J.M. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J. Virol. 2000, 74, 6105-6116.
195. Szretter, K.J.; Gangappa, S.; Lu, X.; Smith, C.; Shieh, W.J.; Zaki, S.R.; Sambhara, S.; Tumpey, T.M.; Katz, J.M. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 2007, 81, 2136-2744.
196. Wolpe, S.D.; Davatelis, G.; Sherry, B.; Beutler, B.; Hesse, D.G.; Nguyen, H.T.; Moldawer, L.L.; Nathan, C.F.; Lowry, S.F.; Cerami, A. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J. Exp. Med. 1988, 167, 570-581.
197. Wolpe, S.D.; Cerami, A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J. 1989, 3, 2565-2573.
198. Rothwell, N.J. Annual review prize lecture cytokines - killers in the brain? J. Physiol. 1999, 514(Pt 1), 3-17.
199. Yuen, K.Y.; Wong, S.S. Human infection by avian influenza A H5N1. Hong Kong Med. J. 2005, 11, 189-199.
200. Guan, Y.; Poon, L.L.; Cheung, C.Y.; Ellis, T.M.; Lim, W.; Lipatov, A.S.; Chan, K.H.; Sturm-Ramirez, K.M.; Cheung, C.L.; Leung, Y.H.; et al. H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA 2004, 101, 8156-8161.
201. Salomon, R.; Hoffmann, E.; Webster, R.G. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Natl. Acad. Sci. USA. 2007, 104, 12479-12481.
202. Marshall-Clarke, S.; Tasker, L.; Buchatska, O.; Downes, J.; Pennock, J.; Wharton, S.; Borrow, P.; Wiseman, D. Z. Influenza H2 haemagglutinin activates B cells via a MyD88-dependent pathway. Eur. J. Immunol. 2006, 36, 95-106.
203. Heer, A.K.; Shamshiev, A.; Donda, A.; Uematsu, S.; Akira, S.; Kopf, M.; Marsland, B.J. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 2007, 178, 2182-2191.
204. Ghosh, T.K.; Mickelson, D.J.; Solberg, J.C.; Lipson, K.E.; Inglefield, J.R.; Alkan, S.S. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int. Immunopharmacol. 2007, 7, 1111-1121.
205. Marshall, J.D.; Heeke, D.S.; Gesner, M.L.; Livingston, B.; Van Nest, G. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J. Leukoc. Biol. 2007, 82, 497-508.
206. Berghöfer, B.; Haley, G.; Frommer, T.; Bein, G.; Hackstein, H. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C- oligodeoxynucleotide-induced IFN-alpha production. J. Immunol. 2007, 178, 4072-4079.
207. Wang, J.; Shao, Y.; Bennett, T.A.; Shankar, R.A.; Wightman, P.D.; Reddy, L.G. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J. Biol. Chem. 2006, 281, 37427-37434.
208. Guerrero-Plata, A.; Baron, S.; Poast, J.S.; Adegboyega, P.A.; Casola, A.; Garofalo, R.P. Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J. Virol. 2005, 79, 10190-10199.
209. Schlender, J.; Hornung, V.; Finke, S.; Gunthner-Biller, M.; Marozin, S.; Brzozka, K.; Moghim, S.; Endres, S.; Hartmann, G.; Conzelmann, K.K. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J. Virol. 2005, 79, 5507-5515.
210. Renshaw, M.; Rockwell, J.; Engleman, C.; Gewirtz, A.; Katz, J.; Sambhara, S. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol. 2002, 169, 4697-4701.
211. Kunder, S.C.; Wu, L.; Morahan, P.S. Protection against murine cytomegalovirus infection in aged mice and mice with severe combined immunodeficiency disease with the biological response modifiers polyribosinic-polycytidylic acid stabilized with L-lysine and carboxymethylcellulose, maleic anhydride divinyl ether and colony stimulating factor 1. Antiviral Res. 1993, 21, 233-245.
212. Chu, R.S.; Targoni, O.S.; Krieg, A.M.; Lehmann, P.V.; Harding, C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Thl) immunity. J. Exp. Med. 1997, 186, 1623-1631.
213. Manning, B.M.; Enioutina, E.Y.; Visic, D.M.; Knudson, A.D.; Daynes, R.A. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp. Gerontol. 2001, 37, 107-126.
214. Maletto, B.; Ropolo, A.; Moron, V.; Pistoresi-Palencia, M.C. CpG-DNA stimulates cellular and humoral immunity and promotes Thl differentiation in aged BALB/c mice. J. Leukoc. Biol. 2002, 72, 447-454.
215. Wong, J.P.; Christopher, M.E.; Salazar, A.M.; Dale, R.M.; Sun, L.Q.; Wang, M. Nucleic acidbased antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007, 25, 3175-3178.
216. Whitmore, M.M.; DeVeer, M.J.; Edling, A.; Oates, R.K.; Simons, B.; Lindner, D.; Williams, B.R. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 2004, 64, 5850-5860.
217. Werling, D.; Hope, J.C.; Howard, C.J.; Jungi, T.W. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Tolllike receptor agonists. Immunology 2004, 111, 41-52.